This week: New cystic fibrosis medication, and seasonal flu outlook
A three-drug combination sold under the brand name Trikafta was recently approved by the Food and Drug Administration for people age 12 and older with cystic fibrosis.
Dr. Christopher Fortner, medical director of the cystic fibrosis program at Upstate, describes how this treatment works, its side effects and what it may mean for many of the people with this disease.
Cystic fibrosis causes persistent lung infections and limits the ability to breathe over time, among other problems.
Also on "HealthLink on Air" this week, Dr. Jarrod Bagatell provides an overview of this year's seasonal influenza and how best to avoid it. Tune in this Sunday, December 1 at 6 a.m. and 9 p.m. for "HealthLink on Air."